SCHEMBL4501023 — predicted protein targets

Predicted protein targets (top 17)

	gene	UniProt	supporting neighbours	confidence
▸	USP2	O75604	1/20	0.56

▸	ALDH1A1	P00352	5/20	0.44

▸	ANPEP	P15144	1/20	0.44

▸	KDM4E	B2RXH2	5/20	0.43

▸	MEN1	O00255	1/20	0.41

▸	KMT2A	Q03164	1/20	0.41

▸	HSD17B10	Q99714	3/20	0.38

▸	ATM	Q13315	3/20	0.37

▸	ALOX15	P16050	1/20	0.36

▸	TSHR	P16473	1/20	0.36

▸	L3MBTL1	Q9Y468	2/20	0.36

▸	LMNA	P02545	2/20	0.36

▸	MAPT	P10636	2/20	0.36

▸	SMN1; SMN2	Q16637	1/20	0.36

▸	HTT	P42858	1/20	0.36

▸	RAB9A	P51151	1/20	0.36

▸	HIF1A	Q16665	1/20	0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL4494214	1.00	USP2 (0.56)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL4494210	0.78	USP2 (0.50)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL4501019	0.78	USP2 (0.50)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL17955613	0.77	USP2 (0.60)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL12518136	0.77	USP2 (0.58)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL4388837	0.76	USP2 (0.78)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL4384137	0.76	USP2 (0.78)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL11186	0.76	USP2 (0.78)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL3101596	0.74	USP2 (0.56)	USP2ALDH1A1ANPEPKDM4EMEN1
SCHEMBL6696413	0.74	USP2 (0.56)	USP2ALDH1A1ANPEPKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-7501516-B2	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-03-10	—	—	US	claimed
EP-1409481-B1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2006-10-04	—	—	EP	claimed
US-20050009867-A1	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2005-01-13	—	—	US	claimed
EP-1409481-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	Astrazeneca AB (SE)	2004-04-21	—	—	EP	claimed
WO-2003008409-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2003-01-30	—	—	WO	claimed
US-7501516-B2	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2009-03-10	—	—	US	disclosed
EP-1409481-B1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2006-10-04	—	—	EP	disclosed
US-20050009867-A1	Quinoline derivatives and their use as tyrosine kinase inhibitors	ASTRAZENECA AB (SE)	2005-01-13	—	—	US	disclosed
EP-1409481-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	Astrazeneca AB (SE)	2004-04-21	—	—	EP	disclosed
WO-2003047582-A1	QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS	ASTRAZENECA AB (SE)	2003-06-12	—	—	WO	disclosed
WO-2003008409-A1	QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS	ASTRAZENECA AB (SE)	2003-01-30	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20050009867-A1	Quinoline derivatives and their use as tyrosine kinase inhibitors	ABL1, FLT3, JAK2	USP2 3379/4885ALDH1A1 3215/4885ANPEP 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.